Rubius Therapeutics
OverviewSuggest Edit
Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
| Type | Public | |
| Founded | 2013 | |
| HQ | Cambridge, MA, US | Map |
| Website | rubiustx.com |
Recent NewsAll News
- Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
- Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
- Thinking about buying stock in Arbutus Biopharma, Aemetis, FuboTV, Rubius Therapeutics, or Lithium Americas Corp?
- Rubius Therapeutics Prices Upsized Public Offering of Common Stock
Key People/Management at Rubius Therapeutics
Pablo J. Cagnoni
Chief Executive Officer, Director
Christina Coughlin
Chief Medical Officer
Andrew Oh
Chief Financial Officer
Kris Elverum
Senior Vice President, Business Development and Strategy
Spencer Fisk
Senior Vice President & Chief Technical Operations Officer
Bryan Gillis
Vice President, Manufacturing
Rubius Therapeutics Office Locations
Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, MA, US (HQ)
399 Binney St #300
Smithfield, RI, US
100 Technology Way
Rubius Therapeutics Financials and Metrics
Rubius Therapeutics Revenue
| USD | |
|---|---|
Net income (FY, 2020) | (167.7m) |
EBIT (FY, 2020) | (166.4m) |
Market capitalization (20-Apr-2021) | 2.2b |
Closing stock price (20-Apr-2021) | 25.1 |
Cash (31-Dec-2020) | 91.2m |
EV | 2.2b |
Rubius Therapeutics's current market capitalization is $2.2 b.
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.1m | 5.8m | 16.3m | 13.2m | 13.5m | 13.8m | 15.0m | 12.7m | 11.6m |
R&D expense | 3.7m | 9.7m | 12.0m | 14.4m | 20.9m | 27.5m | 33.5m | 36.2m | 26.1m |
Operating expense total | 4.8m | 15.4m | 28.2m | 27.6m | 34.4m | 41.3m | 48.5m | 48.9m | 37.7m |
EBIT | (4.8m) | (15.4m) | (28.2m) | (27.6m) | (34.4m) | (41.3m) | (48.5m) | (48.8m) | (37.7m) |
Annual
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.9m) | (15.3m) | (44.4m) | (62.0m) | (32.6m) | (72.0m) | (119.0m) | ||
Depreciation and Amortization | 48.0k | 227.0k | 502.0k | 879.0k | 661.0k | 1.4m | 2.3m | 1.8m | 3.6m |
Accounts Payable | 937.0k | 452.0k | 3.0m | 2.4m | (966.0k) | (4.7m) | 3.2m | 905.0k | 3.1m |
Cash From Operating Activities | (3.1m) | (10.9m) | (20.8m) | (38.6m) | (22.9m) | (52.7m) | (81.5m) | (40.0m) | (68.6m) |
| USD | FY, 2016 |
|---|---|
Debt/Equity | 6.3 x |
Debt/Assets | 1.5 x |
Financial Leverage | 4.1 x |
Rubius Therapeutics Cybersecurity Score
Rubius Therapeutics Environment, Social & Governance (ESG) Ratings
Rubius Therapeutics Online and Social Media Presence
1.23k Twitter followers
Rubius Therapeutics has 1.23k Twitter Followers. The number of followers has increased 8.2% month over month and increased 13.1% quarter over quarter
Rubius Therapeutics's Trends
Twitter Engagement Stats for @rubius_tx
364
Tweets
273
Following
1.2k
Followers
31
Tweets last 30 days
4.3
Avg. likes per Tweet
96.8%
Tweets with engagement
Rubius Therapeutics News and Updates
April 12, 2021
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the fir…
April 09, 2021
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reprised initial clini…
April 01, 2021
Thinking about buying stock in Arbutus Biopharma, Aemetis, FuboTV, Rubius Therapeutics, or Lithium Americas Corp?
NEW YORK, April 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, AMTX, FUBO, RUBY, and LAC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 17, 2021
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
CAMBRIDGE Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announces t…
March 15, 2021
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announces …
March 10, 2021
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Com…
Rubius Therapeutics Blogs
April 10, 2021
A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors
The post A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors appeared first on Rubius Therapeutics.
January 04, 2021
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Content Import
Mon, 01/04/2021 - 16:01
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
This release is a bac…
November 30, 2020
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.
November 20, 2020
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News
Brian.Hoenig@n…
Fri, 11/20/2020 - 09:27
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by…
November 10, 2020
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Content Import
Tue, 11/10/2020 - 16:02
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
November 10, 2020
This release is a backfill from a…
November 09, 2020
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
Content Import
Mon, 11/09/2020 - 08:02
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ C…
Rubius Therapeutics Frequently Asked Questions
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2013.
Who are Rubius Therapeutics key executives?
Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.
How many employees does Rubius Therapeutics have?
Rubius Therapeutics has 174 employees.
Who are Rubius Therapeutics competitors?
Competitors of Rubius Therapeutics include ImCheck Therapeutics, Synartro and InProTher.
Where is Rubius Therapeutics headquarters?
Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.
Where are Rubius Therapeutics offices?
Rubius Therapeutics has offices in Cambridge and Smithfield.
How many offices does Rubius Therapeutics have?
Rubius Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies